Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
February 12, 2018
Arrowhead Pharmaceuticals Reports Fiscal 2018 First Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (ARWR) today announced financial results for its fiscal 2018 first quarter ended December 31, 2017. The company is hosting a ...
February 12, 2018
Neovasc to Present at LEERINK Partners 7th Annual Global Healthcare Conference
VANCOUVER , Feb. 12, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that Fred Colen , President and Chief Executive ...
February 12, 2018
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on February 12, 2018
CRANBURY, N.J., Feb. 12, 2018 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases ...
February 12, 2018
Rexahn Reports Data from the Ongoing Phase 2a Clinical Trial of RX-3117 in Advanced Bladder Cancer at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting
ROCKVILLE, Md., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment ...
February 12, 2018
Opiant Pharmaceuticals Announces Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
SANTA MONICA, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced ...
February 12, 2018
Spring Bank to Host Conference Call to Discuss Fourth Quarter and Fiscal Year 2017 Results on Wednesday, February 21
HOPKINTON, Mass., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, ...
February 12, 2018
Aimmune Therapeutics Announces Presentations at 2018 AAAAI-WAO Joint Congress
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data during a ...
February 12, 2018
AzurRx BioPharma Announces Enrollment of Three New Patients for its Phase IIa Study of MS1819-SD
BROOKLYN, N.Y., Feb. 12, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant ...
February 12, 2018
Advaxis Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for the Treatment of Recurrent Metastatic Cervical Cancer in the International Journal of Gynecological Cancer
PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that data from an earlier Phase ...
February 9, 2018
iCAD Named a Top Artificial Intelligence Medical Imaging Solution Provider by Healthcare Tech Outlook
NASHUA, N.H., Feb. 08, 2018 (GLOBE NEWSWIRE) --  iCAD, Inc. (ICAD), a global leader in medical technology providing innovative cancer detection and therapy solutions, today ...
February 9, 2018
Mirati Therapeutics To Present At Leerink Partners 7th Annual Global Healthcare Conference
SAN DIEGO, Feb. 8, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical stage targeted oncology biotechnology company, will participate in the Leerink Partners 7th Annual ...
February 9, 2018
AzurRx BioPharma to Present at the 2018 BIO CEO & Investor Conference
BROOKLYN, N.Y., Feb. 08, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant ...
February 9, 2018
Catalyst Biosciences Announces Positive Top-Line Data from Phase 1/2 Study of Subcutaneous CB 2679d/ISU304 in Individuals with Hemophilia B
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...
February 9, 2018
Auris Medical Announces Extraordinary General Meeting of Shareholders
Zug, Switzerland, February 9, 2018 - Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in ...
February 6, 2018
Santhera Launches U.S. Expanded Access Program with Idebenone for Patients with Duchenne Muscular Dystrophy (DMD)
Liestal, Switzerland, February 6, 2018 - Santhera Pharmaceuticals (SIX: SANN) announces the launch of a U.S. Expanded Access Program (EAP) referred to as BreatheDMD with idebenone for ...
February 6, 2018
BrainStorm Cell Therapeutics to Present at the BIO CEO & Investor Conference
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Feb. 6, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapeutics for ...
February 6, 2018
Sierra Oncology to host Program Update in New York on February 27th
VANCOUVER, Feb. 6, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) ...
February 6, 2018
BioDelivery Sciences Announces BELBUCA® Patent Litigation Settlement Agreement with Teva
RALEIGH, N.C., Feb. 06, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (BDSI) today announced that it has entered into a Settlement Agreement with Teva ...
February 6, 2018
CytoSorbents to Present at the 20th Annual BIO CEO & Investor Conference
MONMOUTH JUNCTION, N.J., Feb. 6, 2018 /PRNewswire/ -- CytoSorbents Corporation(CTSO), a critical care immunotherapy leader using blood purification to treat deadly inflammation in critically-ill and cardiac ...
February 6, 2018
Zogenix Announces Receipt of FDA Breakthrough Therapy Designation for ZX008 in Dravet Syndrome
EMERYVILLE, Calif., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) ...
Page 98 of 149